Patient-reported Outcomes in Real-world Use of Benralizumab in Patients With Severe Eosinophilic Asthma in Belgium

Completed

• Conditions: Severe Asthma

• Registration Number: NCT04221802
• Lead Sponsor: AstraZeneca

Brief Summary

This study aims to assess health and quality of life outcomes in patients treated with benralizumab, within a Belgian Real-World setting. To prove the clinical value of benralizumab in a Real-World setting, the study will document the effect of benralizumab within a time frame of 112 weeks after initiation of treatment.

Detailed Description

The aim and objective of this single arm, prospective observational study is to provide supporting RWE on the symptom relief of asthma patients qualified for benralizumab therapy in Belgium. The PRO measures consist of the Asthma Control Questionnaire (ACQ 6) as well as Patient Global Impression of Change and Severity (PGI-C and PGI-S), healthcare resource utilization (HCRU) and treatment satisfaction (TSQM-9). In addition change in daily OCS use and rate of exacerbations after initiation of benralizumab in real-world setting will be assessed

Study Timeline

• Study First Submitted: 2019-12-05
• Study Start: 2019-12-23
• Study First Submitted QC: 2020-01-07
• Study First Posted: 2020-01-09
• Primary Completion: 2024-05-13
• Study Completion: 2024-05-13
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-05
• Last Update Posted: 2025-05-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 76

Inclusion Criteria

• Male or female patients 18 years or older with physician's confirmed diagnosis of severe, uncontrolled asthma

• Asthma requiring high dose inhaled corticosteroid plus long-acting β adrenoceptor agonist as maintenance treatment

• A decreased lung function (FEV1 <80%), demonstrated by spirometry in the 12 months before initiation of treatment

• Patients need to fulfil one of the criteria:

  • at least 2 hospitalizations or ER treatments for severe asthma during last 12 months, or
  • at least 2 asthma exacerbations during last 12 months (worsening of asthma with need of systemic corticotherapy for at least 3 days for non cortico-dependent patients, and/or an ER visit and or a hospitalization),
  • or cortico-dependent (at least 6 months treatment with OCS at a daily dose of 4 mg or more of methylprednisolone or 5 mg or more of prednisolone for adults)

• Peripheral blood eosinophil count ≥300cells/μl at initiation of benralizumab treatment and in the year before.

• Obtained reimbursement for treatment with benralizumab

• Provision of signed written informed consent form (ICF) indicating that they understand the purpose of the study and procedures required for participation in the study.

• Patients must be able and willing to read and comprehend written instructions and comprehend and complete the questionnaires required by the protocol.

• Benralizumab naïve and have not previously received benralizumab prior to the start of this study.

Exclusion Criteria

• Patients currently enrolled in an interventional clinical study in parallel (i.e. have not completed) including those with biologic treatment, will be excluded from the study except for patients who are in parallel documented in the Belgian Severe Asthma Registry (BSAR).
• Concurrent biologics for asthma are not allowed except for stable allergen immunotherapy (defined as a stable dose and regimen at the time of enrolment. Acceptable wash-out periods for other asthma biologics:
• ≥30 days from last dose of previous biologic
• Patients with other documented lung disease other than asthma and not within reimbursed label.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
change in patient-reported asthma related symptoms	up to 6 months after initiation of benralizumab	assessed with the Asthma Control Questionnaire (ACQ-6). The primary outcome variable (asthma control responder) is defined as a patient who had an at least (≥) 0.5-unit improvement in ACQ-6 score.

Secondary Outcome Measures

Name	Time	Method
change in daily OCS use following initiation of benralizumab in real-world setting	up to 112 weeks after initiation of benralizumab	Percent change from baseline daily OCS dose
change in asthma status in a real-world setting	up to 112 weeks after initiation of benralizumab	assessed with the Global Impression of Severity (PGI-S). The PGI-S score will be categorized according to the following responses post-baseline: very mild, mild, moderate, severe or very severe.; PGI-S at baseline, week 2, 4, 8, 24, 56, 80 and 112 will be presented descriptively
change of disease severity in a real-world setting	up to 8 weeks after initiation of benralizumab	Assessed with the Global Impression of Change (PGI-C). The PGI-C score will be categorized according to the following responses post-baseline: much better; moderately better; a little better; about the same; a little worse; moderately worse; and much worse.; PGI-C responder endpoint (a little better, moderately better, much better) will be summarised by visit for patients.
Healthcare resource utilization in a real-world setting	up to 112 weeks after initiation of benralizumab	assessed with the Health Care Resource Utilization Questionnaire (HCRU). The HCRU will assess number of asthma-related ED/hospital admissions, number of visits to primary care physician or specialist, number of home visits by health care professional, number of pharmacy visits and number of work/school days lost due to asthma.
change in treatment satisfaction in a real-world setting	up to 112 weeks after initiation of benralizumab	assessed with the Treatment Satisfaction Questionnaire for Medication (TSQM-9). The TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain.; The TSQM-9 scores will be presented descriptively by domain with a focus on efficacy and satisfaction.
Rate of exacerbations after initiation of benralizumab in a real-world setting	up to 112 weeks after initiation of benralizumab	assessed with the Number of exacerbations
Change in patient-reported asthma related symptoms up to 112 weeks after initiation of benralizumab in a real-world setting	up to 112 weeks after initiation of benralizumab	assessed with the Asthma Control Questionnaire (ACQ-6). The primary outcome variable (asthma control responder) is defined as a patient who had an at least (≥) 0.5-unit improvement in ACQ-6 score.

Trial Locations

Locations (1)

Research Site; 🇧🇪 Roeselare, Belgium